Independent register of U.S. FDA drug recalls · updated Oct 10, 2026
RxRecalls Get alerts
Class II · Moderate risk Terminated Initiated Mar 5, 2018 (9 years ago)

methylPREDNISolone Sodium Succinate for Injection

Class II — Moderate risk. May cause temporary or reversible harm; serious harm unlikely.

Why it was recalled

Failed Impurities/Degradation Specifications: High out of specification results for an impurity.

Cause type: Impurity / degradation

An impurity or degradation product above its limit - other than nitrosamines. Unexpected substances in a batch can make it unsafe or less effective, even when the active ingredient is present. All impurity / degradation recalls.

What was recalled

methylPREDNISolone Sodium Succinate for Injection, USP, 125 mg* per vial, Single-Dose Vial, Rx only, Mfd. for: Sagent Pharmaceuticals, Schaumburg, IL 60195 (USA), Made in India. NDC 25021-808-10.

Affected NDC 25021-0808-10

Compare with the code on your package — it is the most precise check available.

Drug: Methylprednisolone

Recalling firm
Sagent Pharmaceuticals Inc
NDC code
25021-808-10
Origin
IL, United States
Initiated by
Voluntary: Firm initiated
FDA recall number
D-0587-2018 · FDA notice

Check, then ask. Class II means harm is possible but usually temporary or reversible. Find the lot number on your package; if it matches, ask your pharmacist about a replacement. Do not simply stop a prescribed medication on your own - the gap can be riskier than the recall. This recall is now terminated, which means the firm has finished removing the affected product; anything on pharmacy shelves today should be unaffected.

Other Methylprednisolone recalls

See all
Class II · Moderate risk

methylprednisolone tablets

Labeling: Not Elsewhere Classified. Incorrect orientation of the blister foil applied to the blister cavities, which results in incorrect dosing information when following the directions on the foil.

Ongoing Labeling / mix-up Greenstone Llc NDC 59762-4440-2 D-0299-2026
Class III · Low risk

Methylprednisolone Acetate Injectable Suspension

Labeling: Not Elsewhere Classified; A typographical error was observed in the NDC number on the preprinted Individual Folding Cartons (secondary packaging only). Incorrect NDC Number 70121-1573-1; Correct NDC Number 70121-1574-1.

Terminated Labeling / mix-up Amneal Pharmaceuticals of New York, LLC NDC 70121-1574-01 D-0756-2023

Other recalls by Sagent Pharmaceuticals Inc

All 2018 recalls
Class I · High risk

Docetaxel Injection

Presence of Particulate Matter: Presence of particulate matter from the stopper in the drug product.

Ongoing Particulate / foreign matter Sagent Pharmaceuticals NDC 25021-254-08 D-0554-2024
Class I · High risk

Docetaxel Injection

Presence of Particulate Matter: Presence of particulate matter from the stopper in the drug product.

Ongoing Particulate / foreign matter Sagent Pharmaceuticals NDC 25021-254-08 D-0553-2024